NASDAQ:PHVS - Nasdaq - NL00150005Y4 - Common Stock - Currency: USD
NASDAQ:PHVS (8/14/2025, 1:20:48 PM)
21.25
-0.18 (-0.84%)
The current stock price of PHVS is 21.25 USD. In the past month the price decreased by -6.83%. In the past year, price increased by 14.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 41.9 | 641.40B | ||
JNJ | JOHNSON & JOHNSON | 17.46 | 420.38B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.62 | 242.60B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.76 | 235.81B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 12.83 | 223.44B | ||
MRK | MERCK & CO. INC. | 10.72 | 207.34B | ||
PFE | PFIZER INC | 7.4 | 142.67B | ||
SNY | SANOFI-ADR | 10.98 | 119.12B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 96.52B | ||
GSK | GSK PLC-SPON ADR | 8.53 | 78.67B | ||
ZTS | ZOETIS INC | 24.38 | 67.51B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.25 | 46.66B |
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 108 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
PHARVARIS NV
Emmy Noetherweg 2
Leiden ZUID-HOLLAND NL
CEO: Berndt Modig
Employees: 83
Phone: 31712036410
The current stock price of PHVS is 21.25 USD. The price decreased by -0.84% in the last trading session.
The exchange symbol of PHARVARIS NV is PHVS and it is listed on the Nasdaq exchange.
PHVS stock is listed on the Nasdaq exchange.
17 analysts have analysed PHVS and the average price target is 33.47 USD. This implies a price increase of 57.53% is expected in the next year compared to the current price of 21.25. Check the PHARVARIS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PHARVARIS NV (PHVS) has a market capitalization of 1.36B USD. This makes PHVS a Small Cap stock.
PHARVARIS NV (PHVS) currently has 83 employees.
PHARVARIS NV (PHVS) has a support level at 20.01 and a resistance level at 21.44. Check the full technical report for a detailed analysis of PHVS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PHVS does not pay a dividend.
PHARVARIS NV (PHVS) will report earnings on 2025-11-11, after the market close.
PHARVARIS NV (PHVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.62).
The outstanding short interest for PHARVARIS NV (PHVS) is 2.37% of its float. Check the ownership tab for more information on the PHVS short interest.
ChartMill assigns a technical rating of 8 / 10 to PHVS. When comparing the yearly performance of all stocks, PHVS is one of the better performing stocks in the market, outperforming 82.35% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to PHVS. The financial health of PHVS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PHVS reported a non-GAAP Earnings per Share(EPS) of -3.62. The EPS decreased by -28.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -61.49% | ||
ROE | -67.7% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to PHVS. The Buy consensus is the average rating of analysts ratings from 17 analysts.